-
The Concept of "Converse Therapeutic Hierarchy" for Patients with Hepatocellular Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2025-05-10 Alessandro Vitale,Giuseppe Cabibbo,Lorenza Rimassa,Massimo Iavarone,Agostino Colli,Laura Crocetti,Timothy M Pawlik,Andrea Casadei-Gardini,Francesca Romana Ponziani,Irene Bargellini,Francesco Tovoli,Umberto Cillo,Edoardo G Giannini
Background The clinical complexity of patients with hepatocellular carcinoma (HCC), the availability of multiple therapeutic options, and clinical therapeutic intents could make it challenging to identify an unequivocal limit between conversion, downstaging/downsizing, and neoadjuvant therapies and curative or palliative intent treatments and to dimension the most proper sequential therapeutic strategy
-
Survival Benefit of Hepatectomy after Complete or Partial Response to Conversion Therapy in Unresectable Hepatocellular Carcinoma (GUIDANCE003): A Multicenter Study. Liver Cancer (IF 11.6) Pub Date : 2025-04-23 Da-Long Yang,Ning Peng,Jun-Liang Nong,Kang Chen,Ze Su,Ya-Qun Yu,Lin Ye,Fan-Jian Zeng,Shao-Ping Liu,Yi-He Yan,Xue-Yao Wang,Hong-Bing Yao,Fu-Quan Yang,Wen-Feng Li,Chuang Qin,Ming-Song Wu,Yong-Yu Yang,Xiao-Feng Dong,Mian-Jing Li,Jie Liu,Yong-Rong Liang,Pei-Sheng Wu,Teng-Meng Zhong,Yong-Cheng Lai,Yao-Zhi Chen,Qing-Qing Pang,Guo-Dong Wang,Fu-Xin Li,Xian-Shuang Mao,Shu-Chang Chen,Jun-Jie Ou,Rong-Rui Huo
Introduction Uncertainty exists regarding whether hepatectomy enhances the prognosis for initially unresectable hepatocellular carcinoma (HCC) that becomes resectable subsequent to conversion therapy. This study conducted a comparative analysis of survival rates between patients who underwent hepatectomy and those who did not, following complete or partial response to conversion therapy. Methods This
-
Comparison of Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging and Contrast-Enhanced Computed Tomography for the Noninvasive Diagnosis of Hepatocellular Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2025-04-22 Jeong Hee Yoon,Won Chang,Young Kon Kim,Chang Hee Lee,Jeong Woo Kim,Beom Jin Park,Jin-Young Choi,Seung-Seob Kim,Hee Sun Park,Eun Sun Lee,Jeong-Sik Yu,Seong Jin Park,Myung-Won You,Myoung-Jin Jang,Joon-Il Choi,Jeong Min Lee
Introduction Magnetic resonance imaging (MRI) has been shown to outperform computed tomography (CT) in diagnosing hepatocellular carcinoma (HCC), although inconsistencies exist across studies. We compared the performance of CT and gadoxetic acid-enhanced MRI in diagnosing HCC according to various guidelines, and to assess the incremental value of a second-line examination. Methods This retrospective
-
Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2025-04-22 Yi-Min Zhang,Xin-Tong Wu,Jun-Zhe Yi,Jie Xu,Yu-Nan Zhang,Ning Lyu,Ming Zhao
Introduction A previous phase 3 FOHAIC-1 study demonstrated that hepatic arterial infusion chemotherapy (HAIC) of FOLFOX regimen displayed favorable outcomes in advanced hepatocellular carcinoma (HCC) patients, including those with high-risk features (main portal tumor invasion and >50% liver infiltration). This study aimed to compare the treatment efficacy of HAIC-FOLFOX versus atezolizumab-bevacizumab
-
Detection of Circulating mRNA Variants in Hepatocellular Carcinoma Patients Using Targeted RNAseq. Liver Cancer (IF 11.6) Pub Date : 2025-04-04 Daniel Zezulinski,Maarouf A Hoteit,David E Kaplan,Angela Simeone,Tingting Zhan,Cataldo Doria,Fowsiyo Y Ahmed,Lewis R Roberts,Timothy M Block,Aejaz Sayeed
Introduction Mutations in circulating nucleic acids can be used as biomarkers for the early detection and management of hepatocellular carcinoma (HCC). However, while circulating tumor DNA and microRNA have been extensively explored, circulating tumor mRNA and circulating mRNA mutants (ctmutRNA), which may provide advantages over other analytes, remain less well described. We previously reported the
-
Comparison of Efficacy between Lenvatinib and Bevacizumab in Combination of Immune Checkpoint Inhibitor and Interventional Triple Therapy in Chinese Advanced Hepatocellular Carcinoma: The CLEAP 2302 Study. Liver Cancer (IF 11.6) Pub Date : 2025-04-03 Zhaolong Pan,Dongming Liu,Junbo Cao,Linlin Fu,Xihao Zhang,Xiaodong Zhu,Yangxun Pan,Jianwei Liu,Chuangye Han,Renan Jin,Shunli Shen,Xiaoyun Zhang,Hongzhi Liu,Xiaobo Yang,Kuan Hu,Xiaoyi Shi,Dongxu Wang,Yang Zhao,Jianhong Zhong,Bangde Xiang,Shanzhi Gu,Tao Li,Shuijun Zhang,Ledu Zhou,Haitao Zhao,Yongyi Zeng,Tianfu Wen,Ming Kuang,Xiao Liang,Tao Peng,Kui Wang,Li Xu,Huikai Li,Tianqiang Song,Huichuan Sun,Wei
Background The conversion therapy for advanced hepatocellular carcinoma (HCC) shows promise with a triple therapy approach that combines interventional therapy, immune checkpoint inhibitors, and molecular targeted therapy (primarily small-molecule TKIs and the large-molecule bevacizumab). This combination has achieved the highest objective response rates (ORR) along with acceptable safety profiles
-
-
Current Surveillance Strategy Is Less Effective for Detecting Early-Stage Hepatocellular Carcinoma in Patients with Non-Viral and Non-Cirrhotic Liver Disease. Liver Cancer (IF 11.6) Pub Date : 2025-03-26 Jessica Spiers,Wenhao Li,Aloysious D Aravinthan,Ayman Bannaga,Katharine Caddick,Emma L Culver,Rosemary E Faulkes,Victoria Gordon,Yaqza Hussain,Hamish Miller,Jenny Merry,Muhammad Saad,Abhishek Sheth,Tahir Shah,Shishir Shetty,Ankur Srivastava,Mohsan Subhani,Muhammad Nauman Tahir,Nwe Ni Than,Esther Unitt,William Alazawi
Introduction Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths. Current international guidelines recommend 6-monthly ultrasound surveillance in all patients with cirrhosis and those with hepatitis B virus-related risk factors to detect early-stage HCC. However, it is unknown whether the benefits of surveillance are comparable across patient groups and underlying disease-related
-
Treatment Decision-Making in Unresectable Hepatocellular Carcinoma: Importance of Understanding the Different Response Patterns between IO plus Anti-VEGF and IO plus IO Regimens. Liver Cancer (IF 11.6) Pub Date : 2025-03-07 Masatoshi Kudo
-
18F-FDG PET/CT Predicts the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation. Liver Cancer (IF 11.6) Pub Date : 2025-03-05 Wen-Jing Zheng,Yang Xu,Hui Tan,Shu-Guang Chen,Peng-Xiang Wang,Hai-Xiang Sun,Rui-Zhe Li,Hai-Ying Zeng,Yu-Chen Zhong,Jian-Wen Cheng,Jia Fan,Jian Zhou,Hongcheng Shi,Xin-Rong Yang
Introduction In addition to radical resection, liver transplantation (LTx) is an effective treatment for hepatocellular carcinoma (HCC). However, tumor recurrence limits the efficacy of LTx in some patients. This study investigated the role of 18F-fludeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in predicting the prognosis of patients with HCC after LTx. Methods A
-
Depth and Duration of Response Are Associated with Survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150. Liver Cancer (IF 11.6) Pub Date : 2025-03-03 Masatoshi Kudo,Tatsuya Yamashita,Richard S Finn,Peter R Galle,Michel Ducreux,Ann-Lii Cheng,Kaoru Tsuchiya,Naoya Sakamoto,Shuhei Hige,Ryosuke Take,Kyoko Yamada,Yuki Nakagawa,Hayato Takahashi,Masafumi Ikeda
Introduction IMbrave150 established first-line atezolizumab plus bevacizumab as a global standard of care for unresectable hepatocellular carcinoma (HCC). We report exploratory analyses of associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR). Methods IMbrave150 was a phase III randomized study of atezolizumab plus bevacizumab versus sorafenib in patients
-
Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2025-03-03 Shuichiro Shiina,Ryosuke Tateishi,Joon Il Choi,So Yeon Kim,Zhiqiang Meng,Lujun Shen,Sheng-Nan Lu,Jen-I Hwang,Maki Tobari,Hitoshi Maruyama,Terguunbileg Batsaikhan,Qing Deng,Lariza Marie Canseco,Yoshinari Asaoka,Shi-Ming Lin,Kai-Wen Huang,Hyunchul Rhim,Ping Liang,Uei Pua,Masatoshi Tanaka,Peihong Wu
Globally, the incidence and associated mortality of primary liver cancer have been steadily increasing. Currently, 80% of cases are found in Asia. Curative resection is applicable in only 20% of patients; therefore, various nonsurgical treatment modalities have been developed. Image-guided percutaneous liver tumor ablation is regarded as the best option for treating early-stage hepatocellular carcinoma
-
Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2024-12-20 Masatoshi Kudo
-
Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence. Liver Cancer (IF 11.6) Pub Date : 2024-10-24 Masatoshi Kudo
-
Incorporating ALBI Grade with Geriatric Nutritional Risk Index Enhances Hepatocellular Carcinoma Risk Stratification. Liver Cancer (IF 11.6) Pub Date : 2024-10-05 Heechul Nam,Pil Soo Sung,Sung Won Lee,Do Seon Song,Jung Hyun Kwon,Jeong Won Jang,Chang Wook Kim,Si Hyun Bae
Introduction Despite its prognostic impact, nutritional status has not yet been integrated into the assessment of hepatocellular carcinoma (HCC). This study investigated the association between geriatric nutritional risk index (GNRI) and overall survival (OS) in patients with HCC using a nationwide registry. Methods Data from the Korea Central Cancer Registry between 2008 and 2019 were analyzed. We
-
The Impact of Radiation Dose and Tumour Burden on Outcomes in Hepatocellular Carcinoma: 11-Year Experience in a 413-Patient Cohort Treated with Yttrium-90 Resin Microsphere Radioembolisation. Liver Cancer (IF 11.6) Pub Date : 2024-09-19 Kaina Chen,Aaron K T Tong,Fiona N N Moe,David C E Ng,Richard H G Lo,Apoorva Gogna,Sean X Yan,Sue Ping Thang,Kelvin S H Loke,Nanda Karaddi Venkatanarasimha,Hian Liang Huang,Chow Wei Too,Timothy S K Ong,Eng Xuan Yeo,Daniel Yang Yao Peh,Ashley W Y Ng,Lu Yang,Wan Ying Chan,Jason P E Chang,Brian K P Goh,Han Chong Toh,Pierce K H Chow
Introduction Transarterial radioembolisation (RE) using yttrium-90 (Y-90) microspheres is a widely used locoregional therapy for a broad spectrum of hepatocellular carcinoma (HCC) given its favourable safety profile. We evaluated the real-world outcomes of unresectable HCC treated with resin Y-90 RE and the relationship between tumour absorbed dose and subsequent curative therapy with survival. Methods
-
Depth of Radiographic Response as an Independent Prognostic Factor for Patients with Initially Unresectable Hepatocellular Carcinoma Receiving Hepatectomy following Targeted Therapy plus Immunotherapy. Liver Cancer (IF 11.6) Pub Date : 2024-09-12 Bin Xu,Lu-Na Wang,Zi-Yi Wang,Tian He,Xiao-Dong Zhu,Ying-Hao Shen,Jian Zhou,Jia Fan,Hui-Chuan Sun,Cheng Huang
Introduction Surgical resection following systemic therapy is feasible in patients with initially unresectable hepatocellular carcinoma (HCC). However, postoperative tumor recurrence is common after surgery, and the factors affecting this recurrence remain unclear. This study aimed to assess factors influencing postoperative outcomes in patients with initially unresectable HCC undergoing hepatectomy
-
Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update. Liver Cancer (IF 11.6) Pub Date : 2024-09-03 Xinyu Bi,Haitao Zhao,Hong Zhao,Guangming Li,Xiaodong Wang,Bo Chen,Wen Zhang,Xu Che,Zhen Huang,Yue Han,Liming Jiang,Yongkun Sun,Zhengqiang Yang,Jianguo Zhou,Yefan Zhang,Zhenyu Zhu,Minshan Chen,Shuqun Cheng,Jianqiang Cai
Hepatocellular carcinoma (HCC) is a common malignancy in China, with high recurrence rate and low resection rate among patients first diagnosed. Preoperative treatments including neoadjuvant and conversion therapy have the potential to overcome these challenges. In December 2021, Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma was published. With the emersion
-
Dynamic Peripheral T-Cell Analysis Identifies On-Treatment Prognostic Biomarkers of Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2024-09-02 Ji Won Han,Min Woo Kang,Soon Kyu Lee,Hyun Yang,Ji Hoon Kim,Jae-Sung Yoo,Hee Sun Cho,Eun Ji Jang,Deok Hwa Seo,Jung Hyun Kwon,Soon Woo Nam,Si Hyun Bae,Jeong Won Jang,Jong Young Choi,Seung Kew Yoon,Pil Soo Sung
Introduction Variability in response to atezolizumab plus bevacizumab (AB) treatment of hepatocellular carcinoma (HCC) underscores the critical need for the development of effective biomarkers. We sought to identify peripheral blood biomarkers reflecting response to AB treatment. Methods We analyzed dynamic changes in peripheral blood mononuclear cells from a prospective, multicenter cohort of 65 patients
-
Particle Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study, Systematic Review and Meta-Analysis. Liver Cancer (IF 11.6) Pub Date : 2024-08-28 Masashi Mizumoto,Kei Shibuya,Kazuki Terashima,Masao Murakami,Motohiro Murakami,Yoshiyuki Shioyama,Yoshiro Matsuo,Takashi Ogino,Tatsuya Ohno,Takahiro Waki,Hiroyuki Ogino,Hiroyasu Tamamura,Norio Katoh,Masaru Wakatsuki,Tomoaki Okimoto,Motohisa Suzuki,Takashi Saito,Shingo Toyama,Takayuki Hashimoto,Hisateru Ohba,Shoji Kubo,Kiyoshi Hasegawa,Kazushi Maruo,Hideyuki Sakurai
Introduction A prospective study was started in May 2016 to evaluate the efficacy and safety of particle therapy for intrahepatic cholangial carcinoma (ICC). To compare treatment modalities, we also conducted a meta-analysis of literature data and a systematic comparison using registry data. Methods Patients who received particle therapy for ICC from May 2016 to June 2018 were registered. Nineteen
-
The Impact of Normal Hepatobiliary Cell Zonation Programs on the Phenotypes and Functions of Primary Liver Tumors. Liver Cancer (IF 11.6) Pub Date : 2024-08-26 Tomoko Aoki,Naoshi Nishida,Yasunori Minami,Masatoshi Kudo
Background Traditional tumor classifications have relied on cellular origin, pathological morphological features, gene expression profiles, and more recently, the tumor immune microenvironment. While these classifications provide valuable insights, incorporating physiological classifications focusing on liver metabolic functions may lead to new discoveries. Summary We proposed to reclassify benign
-
Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries. Liver Cancer (IF 11.6) Pub Date : 2024-08-20 Choong-Kun Lee,Changhoon Yoo,Jung Yong Hong,Se Jun Park,Jin Won Kim,David Wai Meng Tai,Hyeyeong Kim,Krittiya Korphaisarn,Suebpong Tanasanvimon,San-Chi Chen,Ju Won Kim,Ilhwan Kim,Moonho Kim,Joan Choo,Sang-Bo Oh,Ching-Tso Chen,Woo Kyun Bae,Hongsik Kim,Seok Jae Huh,Chia-Jui Yen,Sejung Park,Dong Ki Lee,Landon Long Chan,Beodeul Kang,Minsu Kang,Raghav Sundar,Hye Jin Choi,Stephen Lam Chan,Hong Jae Chon,Myung-Ah
Introduction Atezolizumab plus bevacizumab is a commonly used first-line regimen for advanced hepatocellular carcinoma (HCC) treatment owing to its superior outcomes compared to sorafenib. However, optimal subsequent treatment options for patients with HCC who progressed on first-line atezolizumab plus bevacizumab remain unclear. Methods This multinational, multi-institutional, retrospective study
-
Impact of Diabetes Mellitus and Obesity Comorbidities on Survival Outcomes after Hepatocellular Carcinoma Resection: A Multicenter Retrospective Study. Liver Cancer (IF 11.6) Pub Date : 2024-08-20 Hiroji Shinkawa,Masaki Kaibori,Masaki Ueno,Satoshi Yasuda,Hisashi Ikoma,Tsukasa Aihara,Takuya Nakai,Masahiko Kinoshita,Hisashi Kosaka,Shinya Hayami,Yasuko Matsuo,Ryo Morimura,Takayoshi Nakajima,Chihoko Nobori,Takeaki Ishizawa
Introduction This study aimed to evaluate the association of obesity and diabetes mellitus (DM) comorbidity with hepatocellular carcinoma (HCC) recurrence and survival. Methods We investigated 1,644 patients who underwent hepatic resection for solitary HCC without vascular invasion using computed tomography. Patients were categorized into four groups according to the combination of obesity and DM comorbidities:
-
M2BPGi Correlated with Immunological Biomarkers and Further Stratified Recurrence Risk in Patients with Hepatocellular Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2024-08-14 I-Cheng Lee,Hao-Jan Lei,Lei-Chi Wang,Yi-Chen Yeh,Gar-Yang Chau,Cheng-Yuan Hsia,Shu-Cheng Chou,Jiing-Chyuan Luo,Ming-Chih Hou,Yi-Hsiang Huang
Introduction Novel biomarkers reflecting liver fibrosis and the immune microenvironment may correlate with the risk of hepatocellular carcinoma (HCC) recurrence. This study aimed to evaluate the prognostic value of serum biomarkers in predicting HCC recurrence. Methods Serum biomarkers, including M2BPGi, IL-6, IL-10, CCL5, VEGF-A, soluble PD-1, PD-L1, TIM-3, and LAG-3, were measured in 247 patients
-
The Impact of TP53-Induced Glycolysis and Apoptosis Regulator on Prognosis in Hepatocellular Carcinoma: Association with Tumor Microenvironment and Ferroptosis. Liver Cancer (IF 11.6) Pub Date : 2024-08-12 Katsuya Toshida,Shinji Itoh,Norifumi Iseda,Shugo Tanaka,Kensuke Nakazono,Takahiro Tomiyama,Shohei Yoshiya,Takeo Toshima,Noboru Harada,Kenichi Kohashi,Koji Taniguchi,Yoshinao Oda,Tomoharu Yoshizumi
Introduction TP53-induced glycolysis and apoptosis regulator (TIGAR) is a p53 target protein that has critical roles in glycolysis and redox balance. The reports about the effect of TIGAR on prognosis and its biological role in hepatocellular carcinoma (HCC) are limited. Methods A total of 386 patients with HCC who had undergone hepatic resection were enrolled. Immunohistochemical staining for TIGAR
-
Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2024-08-08 Ghassan K Abou-Alfa,Tim Meyer,Richard Kinh Gian Do,Sarina A Piha-Paul,Joseph S Light,Scott Sherrin,Amin Yaqubie,Alison Clemens O'Neill,James J Harding,Raed Al-Rajabi,Crystal S Denlinger,Pablo Cano,Albert S Cornelius,Eileen M O'Reilly,Daniel DiPrimeo,Lisa D Eli,John D Gordan,David B Solit
Introduction Fibrolamellar carcinoma (FLC) displays upregulation of several oncogenes, including HER2, and multiple immune-suppressive mechanisms. We investigated the efficacy and safety of the pan-HER tyrosine kinase inhibitor neratinib as monotherapy (SUMMIT phase 2 basket study) or with immune checkpoint and/or mammalian target of rapamycin (mTOR) inhibitors (compassionate-use program) in patients
-
Plasma Adiponectin Levels in Relation to Chronic Hepatitis B Infection Progression to Liver Cancer Milestones: A Prospective Study. Liver Cancer (IF 11.6) Pub Date : 2024-06-21 Chi-Ling Chen,Wei-Shiung Yang,Hwai-I Yang,Chuen-Fei Chen,Li-Yu Wang,Sheng-Nan Lu,Jia-Horng Kao,Pei-Jer Chen,Chien-Jen Chen
Introduction Our previous nested-case-control study demonstrated elevated adiponectin increased liver cirrhosis and HCC risk in HBV carriers. We extended the analysis to the whole REVEAL-HBV cohort to prospectively evaluate whether adiponectin directly affected end-stage liver diseases, or through affecting HBV progression. Methods Baseline plasma adiponectin was determined to investigate the association
-
Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150. Liver Cancer (IF 11.6) Pub Date : 2024-06-21 Richard S Finn,Peter R Galle,Michel Ducreux,Ann-Lii Cheng,Norelle Reilly,Alan Nicholas,Sairy Hernandez,Ning Ma,Philippe Merle,Riad Salem,Daneng Li,Valeriy Breder
Introduction Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety in patient subpopulations with Vp4 portal vein tumor thrombosis (PVTT) and other high-risk prognostic factors are reported. Methods IMbrave150 was a global, randomized
-
Cost-Effectiveness of a Biomarker-Based Screening Strategy for Hepatocellular Carcinoma in Patients with Cirrhosis. Liver Cancer (IF 11.6) Pub Date : 2024-06-18 Amit G Singal,Jagpreet Chhatwal,Neehar Parikh,Elliot Tapper
Introduction Given suboptimal performance of ultrasound-based surveillance for early hepatocellular carcinoma (HCC) detection in patients with cirrhosis, there is interest in alternative surveillance strategies, including blood-based biomarkers. We aimed to evaluate the cost-effectiveness of biomarker-based surveillance in patients with cirrhosis. Methods We constructed a decision-analytic model to
-
Prognostic Efficacy of the Albumin-Bilirubin Score and Treatment Outcomes in Hepatocellular Carcinoma: A Large-Scale, Multi-Center Real-World Database Study. Liver Cancer (IF 11.6) Pub Date : 2024-06-14 Kyu-Pyo Kim,Kang Mo Kim,Baek-Yeol Ryoo,Won-Mook Choi,Won Chul Cha,Mira Kang,Dong Hyun Sinn,Myung Ji Goh,Do Young Kim,Min Ji Lee,Subin Lim,DongKyu Kim,Kyoungdae Baek,Joohyun Kim,Eui Jun Choi,Doik Lee,Jung-Ae Kim,Ki-Hun Kim
Introduction Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality globally, with treatment outcomes closely tied to liver function. This study evaluates the prognostic utility of the albumin-bilirubin (ALBI) score compared to the traditional Child-Pugh (CP) grading, leveraging real-world evidence from a large-scale, multi-center database. Methods The Liver Cancer IN Korea
-
LI-RADS Category Can Be a Post-Surgical Prognostic Factor for Intrahepatic Cholangiocarcinoma in Patients with Liver Cirrhosis or Chronic Hepatitis B. Liver Cancer (IF 11.6) Pub Date : 2024-06-14 Sungeun Park,Boyeon Koo,Boryeong Jeong,Sang Hyun Choi,Jeong Min Lee
Introduction The Liver Imaging Reporting and Data System (LI-RADS) categorization has been proposed as a potential prognostic indicator for primary liver neoplasms in patients with liver cirrhosis or chronic hepatitis B. This multicenter study aimed to determine whether LI-RADS categorization can offer additional post-surgical prognostic value for intrahepatic cholangiocarcinoma (ICCA) when used in
-
Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis. Liver Cancer (IF 11.6) Pub Date : 2024-05-22 Young-Gi Song,Kyeong-Min Yeom,Eun Ae Jung,Sang Gyune Kim,Young Seok Kim,Jeong-Ju Yoo
Introduction The combination of atezolizumab/bevacizumab has emerged as an effective first-line treatment for advanced hepatocellular carcinoma (HCC). However, this therapy is potentially associated with bleeding complications, warranting a comprehensive analysis of their incidence and severity. This meta-analysis aims to synthesize available evidence from clinical trials and observational studies
-
Assessment of Macrovascular Invasion in Advanced Hepatocellular Carcinoma: Clinical Implications and Treatment Outcomes with Systemic Therapy. Liver Cancer (IF 11.6) Pub Date : 2024-05-21 Masanori Inoue,Sadahisa Ogasawara,Kazufumi Kobayashi,Tomomi Okubo,Norio Itokawa,Masamichi Obu,Kentaro Fujimoto,Hidemi Unozawa,Sae Yumita,Kisako Fujiwara,Miyuki Nakagawa,Hiroaki Kanzaki,Keisuke Koroki,Soichiro Kiyono,Masato Nakamura,Naoya Kanogawa,Takayuki Kondo,Shingo Nakamoto,Kengo Nagashima,Ei Itobayashi,Masanori Atsukawa,Yoshihiro Koma,Ryosaku Azemoto,Naoya Kato
Introduction Macrovascular invasion (MVI) is a strong prognostic factor for advanced hepatocellular carcinoma (HCC). The current criteria for radiological assessment are unclear in evaluating the impact of MVI on systemic therapy. In this study, we standardized the assessment of MVI and validated its clinical relevance. Methods Clinical data were collected from patients with advanced HCC and MVI who
-
Clinical Utility of the Novel Oncological Criteria of Resectability for Advanced Hepatocellular Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2024-05-16 Junichi Shindoh,Yusuke Kawamura,Keiichi Akahoshi,Masaru Matsumura,Satoshi Okubo,Norio Akuta,Minoru Tanabe,Norihiro Kokudo,Yoshiyuki Suzuki,Masaji Hashimoto
Introduction Introduction of new systemic therapies for hepatocellular carcinoma (HCC) has led to the development of new oncological criteria of resectability for the resectability of HCC. This study was aimed at validating the prognosticating ability and clinical utility of the resectability classification based on the novel criteria in real-world clinical practice. Methods This study was conducted
-
A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization). Liver Cancer (IF 11.6) Pub Date : 2024-05-13 Masatoshi Kudo
-
Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study". Liver Cancer (IF 11.6) Pub Date : 2024-05-06 Masatoshi Kudo,Kaoru Tsuchiya,Tatsuya Yamashita,Hironori Koga,Yuki Nakagawa,Masafumi Ikeda
-
Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2024-04-17 Masatoshi Kudo
-
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study. Liver Cancer (IF 11.6) Pub Date : 2024-04-10 Federico Rossari,Toshifumi Tada,Goki Suda,Shigeo Shimose,Masatoshi Kudo,Changhoon Yoo,Jaekyung Cheon,Fabian Finkelmeier,Ho Yeong Lim,José Presa,Gianluca Masi,Francesca Bergamo,Elisabeth Amadeo,Francesco Vitiello,Takashi Kumada,Naoya Sakamoto,Hideki Iwamoto,Tomoko Aoki,Hong Jae Chon,Vera Himmelsbach,Massimo Iavarone,Giuseppe Cabibbo,Margarida Montes,Francesco Giuseppe Foschi,Caterina Vivaldi,Caterina
Introduction The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post hoc analyses of IMbrave-150 and metanalyses of clinical trials of PD-1/PD-L1 blockers. As a results, it is not clear whether the first-line systemic treatment atezolizumab plus bevacizumab (A + B) is equally effective in
-
Oncological Resectability Criteria for Hepatocellular Carcinoma in the Era of Novel Systemic Therapies: The Japan Liver Cancer Association and Japanese Society of Hepato-Biliary-Pancreatic Surgery Expert Consensus Statement 2023. Liver Cancer (IF 11.6) Pub Date : 2024-03-29 Keiichi Akahoshi,Junichi Shindoh,Minoru Tanabe,Shunichi Ariizumi,Susumu Eguchi,Yukiyasu Okamura,Masaki Kaibori,Shoji Kubo,Mitsuo Shimada,Akinobu Taketomi,Nobuyuki Takemura,Hiroaki Nagano,Masafumi Nakamura,Kiyoshi Hasegawa,Etsuro Hatano,Tomoharu Yoshizumi,Itaru Endo,Norihiro Kokudo
Recent advances in systemic therapy for hepatocellular carcinoma (HCC) have led to debates about the feasibility of combination therapies, such as systemic therapy combined with surgery or transarterial chemoembolization, for patients with advanced HCC. However, a lack of consensus on the oncological resectability criteria has hindered discussions of "conversion therapy" and the optimal management
-
Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification. Liver Cancer (IF 11.6) Pub Date : 2024-03-12 Byeong Geun Song,Aryoung Kim,Myung Ji Goh,Wonseok Kang,Geum-Youn Gwak,Yong-Han Paik,Moon Seok Choi,Joon Hyeok Lee,Dong Hyun Sinn
Introduction Steatotic liver disease (SLD) is a new overarching term proposed to replace nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease. Subclassification includes metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD), and cryptogenic SLD. This study aimed to investigate whether SLD and its subclassification could stratify
-
Characterization of Tumor Responses in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in the Phase 3 Randomized Trial: REFLECT. Liver Cancer (IF 11.6) Pub Date : 2024-02-26 Richard S Finn,Shukui Qin,Fabio Piscaglia,Thomas R Jeffry Evans,Jennifer J Knox,Carlos López López,Zahra Ramji,Min Ren,Kalgi Mody,Arndt Vogel,Masatoshi Kudo
Introduction In REFLECT, lenvatinib was noninferior to sorafenib in terms of overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC; median 13.6 vs. 12.3 months; HR 0.92, 95% CI 0.79-1.06). The objective response rate (ORR) with lenvatinib was 18.8% by blinded independent imaging review (IIR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1); per
-
Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2024-02-20 Masatoshi Kudo
-
Combination Assay of Methylated HOXA1 with Tumor Markers Shows High Sensitivity for Detection of Early-Stage Hepatocellular Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2024-02-14 Yuki Kunimune,Yutaka Suehiro,Issei Saeki,Yurika Yamauchi,Norikazu Tanabe,Toshihiko Matsumoto,Shingo Higaki,Ikuei Fujii,Chieko Suzuki,Naoko Okayama,Mitsuaki Nishioka,Kiyoshi Ichihara,Hiroaki Nagano,Isao Sakaida,Taro Takami,Takahiro Yamasaki
Introduction Patients with hepatitis virus-related hepatocellular carcinoma (viral HCC) are decreasing as hepatitis control improves, but those with non-viral-related HCC (non-viral HCC) are increasing in Japan. No established surveillance system exists for patients with non-viral HCC, so they are often diagnosed at an advanced stage. To address this, we performed this study. Methods We collected serum
-
Management Consensus Guidelines for Hepatocellular Carcinoma: 2023 Update on Surveillance, Diagnosis, Systemic Treatment, and Posttreatment Monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. Liver Cancer (IF 11.6) Pub Date : 2024-02-12 Wei Teng,Hung-Wei Wang,Shi-Ming Lin,
Hepatocellular carcinoma (HCC) is the leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan established HCC management consensus guidelines in 2016 and updated them in 2023. Current recommendations focus on addressing critical issues in HCC management, including surveillance, diagnosis, systemic treatment, and posttreatment
-
Surveillance for Hepatocellular Carcinoma in Patients with Successfully Treated Viral Disease of the Liver: A Systematic Review. Liver Cancer (IF 11.6) Pub Date : 2024-02-06 Lorenzo Lani,Benedetta Stefanini,Franco Trevisani
Background Surveillance for hepatocellular carcinoma (HCC) has been proven to increase the proportion of tumors detected at early stages and the chance of receiving curative therapies, reducing mortality by about 30%. Summary Current recommendations consist of a semi-annual abdominal ultrasound with or without serum alpha-fetoprotein measurement in patients with cirrhosis and specific subgroups of
-
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression. Liver Cancer (IF 11.6) Pub Date : 2024-02-01 Tsung-Hao Liu,San-Chi Chen,Kun-Ming Rau,Li-Chun Lu,Po-Ting Lin,Yung-Yeh Su,Wei Teng,Shiue-Wei Lai,Ren-Hua Yeh,Tsui-Mai Kao,Pei-Chang Lee,Chi-Jung Wu,Chien-Hung Chen,Chih-Hung Hsu,Shi-Ming Lin,Yi-Hsiang Huang,Li-Tzong Chen,Ann-Lii Cheng,Ying-Chun Shen,
Introduction The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized. Methods Patients with advanced HCC who received immune checkpoint inhibitor (ICI)-based immunotherapy and achieved durable responses were retrospectively included. A durable response was defined as partial
-
A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial. Liver Cancer (IF 11.6) Pub Date : 2024-01-29 Zhi-Mei Huang,Xue Han,Jian Wang,Ling Gu,Lu Tang,Shao-Yong Wu,Tian Di,Ying-Wen Hou,Wan Yee Lau,Yi-Quan Jiang,Jin-Hua Huang
Introduction For patients with large unresectable hepatocellular carcinoma (HCC), the effectiveness of conventional transarterial chemoembolization (cTACE) remains suboptimal. This study investigated the efficacy and safety of modified TACE using low-dose chemotherapy with blank microspheres (BMS-TACE) plus low-dose lenvatinib (LD-LEN) and microwave ablation (MWA) in patients with large unresectable
-
Prognostic Value of Pathological Response for Patients with Unresectable Hepatocellular Carcinoma Undergoing Conversion Surgery. Liver Cancer (IF 11.6) Pub Date : 2024-01-27 Zhen-Xin Zeng,Jia-Yi Wu,Jun-Yi Wu,Zhi-Bo Zhang,Kai Wang,Shao-Wu Zhuang,Bin Li,Jian-Yin Zhou,Zhong-Tai Lin,Shu-Qun Li,Yi-Nan Li,Yang-Kai Fu,Mao-Lin Yan
Introduction Transarterial chemoembolization combined with lenvatinib and PD-1 inhibitor (triple therapy) has displayed encouraging clinical outcomes for unresectable hepatocellular carcinoma (uHCC). We aimed to explore the prognostic value of pathological response (PR) in patients with initially uHCC who underwent conversion surgery following triple therapy and identify predictors of major pathological
-
Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition). Liver Cancer (IF 11.6) Pub Date : 2024-01-16 Xiufeng Liu,Yinying Lu,Weiping Zhou,Tao Peng,Jie Zhou,Huaqiang Bi,Feng Xia,Xiaoping Chen
Background Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC. Summary To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated
-
A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394. Liver Cancer (IF 11.6) Pub Date : 2024-01-10 Shukui Qin,Weijia Fang,Zhenggang Ren,Shuangyan Ou,Ho Yeong Lim,Feng Zhang,Kin Chung Lee,Hye Jin Choi,Jiandong Tong,Min Tao,Aibing Xu,Ashley Cheng,Chang-Hsien Lu,Chang-Fang Chiu,Mohamed Ibrahim Abdul Wahid,Shital Kamble,Josephine M Norquist,Wenyan Zhong,Chen Li,Zhendong Chen
Introduction KEYNOTE-394 showed pembrolizumab significantly improved overall survival, progression-free survival, and objective response rate with manageable safety versus placebo for patients from Asia with previously treated advanced hepatocellular carcinoma. We present results on health-related quality of life (HRQoL). Methods HRQoL was evaluated using the EORTC Quality of Life Questionnaire-Core
-
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study. Liver Cancer (IF 11.6) Pub Date : 2023-12-22 Gi-Ae Kim,Seogsong Jeong,Heejoon Jang,Dong Hyeon Lee,Sae Kyung Joo,Won Kim
Introduction This study aimed to investigate the liver-related outcomes of newly suggested metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD), as well as alcohol-associated liver disease (ALD). Methods From a National Health Insurance Service Health Screening Cohort, we included 369,094 participants who underwent health checkups between
-
Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study. Liver Cancer (IF 11.6) Pub Date : 2023-12-21 Heechul Nam,Jaejun Lee,Ji Won Han,Soon Kyu Lee,Hyun Yang,Hae Lim Lee,Pil Soo Sung,Hee Yeon Kim,Seok-Hwan Kim,Myeong Jun Song,Jung-Hyun Kwon,Chang Wook Kim,Soon Woo Nam,Si Hyun Bae,Jong Young Choi,Seung Kew Yoon,Jeong Won Jang
Introduction Despite the emergence of atezolizumab and bevacizumab (A + B) as standard first-line systemic therapy for unresectable hepatocellular carcinoma (HCC), a comprehensive understanding of the clinical significance of immune-related adverse events (irAEs) remains limited. We aimed to assess the impact of irAEs on patients with HCC undergoing A + B treatment. Methods This multicentre retrospective
-
Objective Response to Systemic Therapy Is a Strong Predictor of Overall Survival in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2023-11-29 Masatoshi Kudo
-
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study. Liver Cancer (IF 11.6) Pub Date : 2023-11-28 Masatoshi Kudo,Kaoru Tsuchiya,Yu-Yun Shao,Richard S Finn,Peter R Galle,Michel Ducreux,Ann-Lii Cheng,Tatsuya Yamashita,Hironori Koga,Ryosuke Take,Kyoko Yamada,Takashi Asakawa,Yuki Nakagawa,Masafumi Ikeda
Introduction The phase III IMbrave150 study established atezolizumab + bevacizumab as the global standard of care in patients with unresectable hepatocellular carcinoma (HCC). This exploratory analysis examined the impact of bevacizumab interruption due to bevacizumab adverse events of special interest (AESIs). Methods Patients in IMbrave150 who were randomized to atezolizumab + bevacizumab and received
-
A Multicenter Phase 2 Trial Evaluating the Efficacy and Safety of Preoperative Lenvatinib Therapy for Patients with Advanced Hepatocellular Carcinoma (LENS-HCC Trial). Liver Cancer (IF 11.6) Pub Date : 2023-11-28 Akihiko Ichida,Junichi Arita,Etsuro Hatano,Susumu Eguchi,Akio Saiura,Hiroaki Nagano,Junichi Shindoh,Masaji Hashimoto,Nobuyuki Takemura,Kojiro Taura,Yoshihiro Sakamoto,Yu Takahashi,Yasuji Seyama,Yasuharu Sasaki,Kohei Uemura,Norihiro Kokudo,Kiyoshi Hasegawa
Introduction The phase III REFLECT trial demonstrated that lenvatinib was superior to sorafenib in terms of progression-free survival (PFS), time to progression, and objective response rate (ORR) for patients with unresectable hepatocellular carcinoma (HCC). This study assessed the efficacy and safety of preoperative lenvatinib therapy for patients with oncologically or technically unresectable HCC
-
A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116. Liver Cancer (IF 11.6) Pub Date : 2023-11-13 Masatoshi Kudo,Richard S Finn,Masafumi Ikeda,Max W Sung,Ari D Baron,Takuji Okusaka,Masahiro Kobayashi,Hiromitsu Kumada,Shuichi Kaneko,Marc Pracht,Tim Meyer,Satoshi Nagao,Kenichi Saito,Kalgi Mody,Zahra Ramji,Leonid Dubrovsky,Josep M Llovet
Introduction Lenvatinib (dosing for patients who weigh ≥60 kg was 12 mg/day; for patients who weigh <60 kg, the dose was 8 mg/day) plus pembrolizumab 200 mg once every 3 weeks demonstrated antitumor activity and a manageable safety profile in patients with first-line unresectable hepatocellular carcinoma (uHCC) in the open-label phase 1b Study 116/KEYNOTE-524 (primary analysis data cutoff date: October
-
Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy? Liver Cancer (IF 11.6) Pub Date : 2023-11-13 Sang Youn Hwang,Sangjune L Lee,Hongqun Liu,Samuel S Lee
Background Immune checkpoint inhibitor (ICI)-based therapy such as atezolizumab plus bevacizumab or durvalumab plus tremelimumab became mainstream first-line systemic treatment in advanced hepatocellular carcinoma (HCC) patients since remarkably superior efficacy of ICI-based therapy compared to tyrosine kinase inhibitors (TKIs) was reported in two recent randomized controlled trials (RCTs) (IMbrave150
-
Impact of Liver Fibrosis Severity on Oncological Prognosis in Hepatocellular Carcinoma. Liver Cancer (IF 11.6) Pub Date : 2023-10-31 Koya Yasukawa,Akira Shimizu,Koji Kubota,Tsuyoshi Notake,Kiyotaka Hosoda,Hikaru Hayashi,Yuji Soejima
Introduction Cirrhosis is deemed to be a contributing factor to the postoperative recurrence of hepatocellular carcinoma (HCC); however, the precise impact of liver fibrosis on both cancer-specific prognoses remains unclear. This investigation sought to elucidate the effect of liver fibrosis severity on the cancer-specific prognosis. Methods A total of 524 consecutive patients were included. Recurrence-free
-
Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection Exhibited Favorable Survival from Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Liver Cancer (IF 11.6) Pub Date : 2023-10-30 Qi Du,Jia Yuan,Zhenggang Ren
Background Immune checkpoint inhibitors (ICIs) have demonstrated effectiveness for advanced hepatocellular carcinoma (HCC). However, the discrepancy in the efficacy of ICIs in HCC patients with distinct etiologies has not been systematically validated. Methods PubMed, MEDLINE, Embase, clinicaltrials.gov, and abstracts from ASCO and ESMO conferences were searched for eligible trials that explored the
-
Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis. Liver Cancer (IF 11.6) Pub Date : 2023-10-14 Andrea Pasta,Francesco Calabrese,Ariel Jaffe,Sara Labanca,Simona Marenco,Giulia Pieri,Maria Corina Plaz Torres,Mario Strazzabosco,Edoardo G Giannini
Background Safety and outcome of atezolizumab/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma (HCC) have not been completely characterized. Objectives In this study, we aimed at addressing safety and efficacy of atezolizumab/bevacizumab in Child-Pugh B patients by reviewing the available data and analyzing them by meta-analysis. Methods We compared the safety and efficacy of ate